Skip to main content
. 2015 May 5;11:713–729. doi: 10.2147/TCRM.S68130

Table 4.

Response rates and adverse events in palonosetron-only studies

Study Intervention CR – acute (%) CC – acute (%) CR – delayed (%) CC – delayed (%) Adverse events
Eisenberg et al13 1) Palonosetron 0.3–1.0 μg/kg 24a Not specified. Only stated CC slightly lower than rates of CR n/a n/a Headache (19.3%), constipation (8.7%), abdominal pain (2.5%), dizziness (2.5%)
2) Palonosetron 3 μg/kg 46a
3) Palonosetron 10 μg/kg 40a
4) Palonosetron 30 μg/kg 50
5) Palonosetron 90 μg/kg 46a
Hesketh et al18 Palonosetron 0.25 mg IV 88.2 85.3 67.6 64.7 Decreased appetite (5.6%), fatigue (5.6%), headache (5.6%), pyrexia (5.6%)
Di Renzo et al9 Palonosetron 0.25 mg IV 90.7 89.5 88.4 84.9 Constipation (7.0%), headache (5.8%), asthenia (7.0%), dizziness (1.2%)
Boccia et al19,b 1) Palonosetron 0.25 mg oral 70.1 n/a 61.0 n/a Headache (3.7%–8.6%), constipation (0.6%–3.2%)
2) Palonosetron 0.50 mg oral 66.7 61.7
3) Palonosetron 0.75 mg oral 62.8 56.4
4) Palonosetron 0.25 mg IV 57.5 62.5
Eisenberg et al20 1) Palonosetron 0.25 mg IV 63.0a n/a 54.0 n/a Headache (24.1%–26.8%), constipation (9.3%–14.9%), fatigue (10.9%–13.3%)
2) Palonosetron 0.75 mg IV 57.1a 56.6
3) Dolasetron 100 mg 52.9a 38.7
Gralla et al21 1) Palonosetron 0.25 mg IV 81.0 n/a 74.1 n/a Headache (4.8%–5.3%)
2) Palonosetron 0.75 mg IV 73.5a 64.6a
3) Ondansetron 32 mg 68.6 55.1
Choi et al22 1) Palonosetron 0.25 mg IV day 1 cycle 1 77.3 n/a 83.0 n/a Constipation (2.3%), fatigue (1.1%)
2) Palonosetron 0.25 mg IV day 1 cycle 2 84.1 93.9
3) Palonosetron 0.25 mg IV day 1 cycle 3 82.1 92.3
4) Palonosetron 0.25 mg IV day 1 cycle 4 84.1 94.2
Mattiuzzi et al23 1) Ondansetron 8 mg IV n/a n/a 21a n/a Constipationc, headachec
2) Palonosetron 0.25 mg IV from day 1 to day 5 31a
3) Palonosetron 0.25 mg IV on days 1, 3, and 5 35a
Dong et al24 1) Palonosetron 0.25 mg IV 95.4a 90.9a 84.1 79.5 Constipation (15.7%), headache (4.5%), anxiety (2.3%)
2) Ondansetron 8 mg IV 93.3a 91.9a 60.0 55.5
Tian et al25 1) Palonosetron 0.25 mg IV n/a 66.41a n/a 53.91a Leukopenia (12.50%–15.94%), constipation (8.70%–10.16%), fatigue (8.59%–9.42%), alanine or aspartate aminotransferase elevation (6.52%–7.81%), abnormal ECG recordings (5.07%–7.81%), dizziness (7.03%–10.87%), headache (5.80%–6.25%), anemia (4.69%–6.52%), thrombocytopenia (0.78%–6.52%)
2) Granisetron 3 mg IV 62.32a 52.17a

Notes:

a

Not statistically significant;

b

this study was included in the dexamethasone and palonosetron combination section as well;

c

didn’t state proportion of patients experiencing these symptoms.

Abbreviations: CC, complete control; CR, complete response; ECG, electrocardiogram; IV, intravenous; n/a, not available.